Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the quality of life in renal transplant recipients who require a
reduced dose of mycophenolate mofetil (MMF) because of gastrointestinal (GI) side effects and
will also access the relationship between mycophenolic acid (MPA) dose in those patients
receiving enteric-coated mycophenolate sodium formulation(EC-MPS).
Patients will be evaluated at baseline, 2 weeks after study medicine conversion and then
again at 12 weeks post-conversion.